Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer: Predicting Response with in Vivo¹H MR Spectroscopy—A Pilot Study at 4 T

Abstract

These results suggest that the change in tCho concentration between baseline and 24 hours after the first dose of PST can serve as an indicator for predicting clinical response to doxorubicin-based chemotherapy in locally advanced breast cancer.

Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy

“…Such studies have recently been carried out in breast cancer (Jagannathan et al, 2001;Meisamy et al, 2004), lymphoma and germ cell tumours (Schwarz et al, 2002), and glioma (Preul et al, 2000), where positive treatment response has been associated with reduction in the levels of total choline. Similar studies using phosphorous spectroscopy to detect changes in phosphocholine or phosphomonoesters have also been carried out in lymphoma (Arias-Mendoza et al, 2004) and head and neck cancer (Shukla-Dave et al, 2002a, b).…”

“…Proton magnetic resonance spectroscopy (MRS) can be used to characterise breast lesions through differences in the ratio of fat and water signals (Chu et al, 1987;Sijens et al, 1988) or the intensity of signal from choline-containing compounds (Bradamante et al, 1988;Katz-Brull et al, 2002;Bolan et al, 2003;Jacobs et al, 2004;Jacobs et al, 2005). Both fat : water ratios (Jagannathan et al, 1998) and choline levels (Preul et al, 2000;Jagannathan et al, 2001;Schwarz et al, 2002;Meisamy et al, 2004) have also been used to monitor treatment-induced changes, and phosphorous MRS has been used to predict response using differences in the levels of phosphocholine or phosphomonoesters (Shukla-Dave et al, 2002a, b;Arias-Mendoza et al, 2004). Sodium MRI might also be useful in monitoring treatment response (Kline et al, 2000;Schepkin et al, 2005).…”

Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy

“…Because only a handful of these agents have so far gained FDA approval, and the fact that most are still in pre-clinical development or early-phase clinical testing, most of the MRS studies performed to date have been concerned with pre-clinical cancer models, including cells and tumour xenografts. However, the technology has been demonstrated in a range of diagnostic and response assessment clinical studies (Howe et al, 2003;Meisamy et al, 2004;Vilanova et al, 2009).…”

Reproducibility of total choline/water ratios in mouse U87MG xenograft tumors by 1H‐MRS

“…THE PHOSPHOLIPID PRECURSOR phosphocholine (PCho) has been identified as being a well-validated metabolic biomarker of human cancers including breast, brain, ovarian, gastric, and prostate tumors (1)(2)(3)(4)(5)(6). These tumors have been identified to have significantly higher concentrations of PCho compared to their matched normal tissues.…”

“…Numerous studies have also demonstrated that 1 H-MRS can be used clinically to diagnose human cancers, monitor responses to therapy, and investigate tumor metabolism by measuring tumor choline metabolites (2)(3)(4)18). These studies have identified changes in tumor choline metabolites as being a key feature of human cancers that can be used to distinguish normal cells from cancer cells (1,7) as well as to assess responses to therapy.…”